Blood coagulation disease
MONDO:0001531A condition in which there is a deviation from or interruption of the normal coagulation properties of the blood.
Also known as: blood coagulation disorder, coagulation defect, coagulation disorder, coagulation disorder, blood, coagulation disorders, blood, coagulopathy, disorder, blood coagulation, disorders, blood coagulation
539 clinical trials for this condition and its sub-types, 54 tagged with Blood coagulation disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Blood coagulation disease
-
Inherited blood coagulation disorder 8 trials · 321 incl. sub-types
39 sub-types
- Hemophilia A 178 trials Sub-types →
- Hemophilia B 84 trials · 91 incl. sub-types Sub-types →
- Hereditary von Willebrand disease 18 trials · 29 incl. sub-types Sub-types →
- Inherited thrombophilia 0 trials · 28 incl. sub-types Sub-types →
- Hereditary hemolytic uremic syndrome 0 trials · 19 incl. sub-types Sub-types →
- Wiskott-Aldrich syndrome 10 trials
- Glanzmann thrombasthenia 8 trials Sub-types →
- Platelet-type bleeding disorder 10 8 trials
- Congenital thrombotic thrombocytopenic purpura 5 trials
- Hereditary thrombocytopenia and hematologic cancer predisposition syndrome 1 trial · 5 incl. sub-types Sub-types →
- Hermansky-Pudlak syndrome 4 trials Sub-types →
- Congenital vitamin K-dependent coagulation factors deficiency 0 trials · 4 incl. sub-types Sub-types →
- Congenital factor XII deficiency 1 trial
- Congenital plasminogen activator inhibitor type 1 deficiency 1 trial
- Hypoplasminogenemia 1 trial
- Ehlers-Danlos syndrome, fibronectinemic type 0 trials
- Scott syndrome 0 trials
- Tatsumi factor deficiency 0 trials
- Alpha-2-plasmin inhibitor deficiency 0 trials
- Congenital factor V deficiency 0 trials
- Congenital factor XI deficiency 0 trials
- Congenital high-molecular-weight kininogen deficiency 0 trials
- Cytosolic phospholipase-A2 alpha deficiency associated bleeding disorder 0 trials
- Dysplasminogenemia 0 trials
- Factor 5 and Factor VIII, combined deficiency of, 2 0 trials
- Factor V and factor VIII, combined deficiency of, type 1 0 trials
- Factor VII and Factor VIII, combined deficiency of 0 trials
- Factor XIII, A subunit, deficiency of 0 trials
- Factor XIII, b subunit, deficiency of 0 trials
- Familial thrombomodulin anomalies 0 trials
- Hereditary thrombocytosis with transverse limb defect 0 trials
- Hypercoagulability syndrome due to glycosylphosphatidylinositol deficiency 0 trials
- Inherited prekallikrein deficiency 0 trials
- Plasminogen deficiency, type II 0 trials
- Platelet-type bleeding disorder 12 0 trials
- Platelet-type bleeding disorder 14 0 trials
- Platelet-type bleeding disorder 16 0 trials
- Platelet-type bleeding disorder 18 0 trials
- Platelet-type bleeding disorder 8 0 trials
-
Coagulation protein disease 13 trials · 272 incl. sub-types
28 sub-types
- Hemophilia 55 trials · 214 incl. sub-types Sub-types →
- Von Willebrand disease (hereditary or acquired) 39 trials · 46 incl. sub-types Sub-types →
- Acquired coagulation factor deficiency 4 trials · 15 incl. sub-types Sub-types →
- Congenital fibrinogen deficiency 2 trials · 6 incl. sub-types Sub-types →
- Factor VII deficiency 6 trials Sub-types →
- Thrombophilia due to activated protein C resistance 5 trials
- Congenital vitamin K-dependent coagulation factors deficiency 0 trials · 4 incl. sub-types Sub-types →
- Factor X deficiency 2 trials Sub-types →
- Congenital factor XII deficiency 1 trial
- Congenital plasminogen activator inhibitor type 1 deficiency 1 trial
- Hypoplasminogenemia 1 trial
- East Texas bleeding disorder 0 trials
- Tatsumi factor deficiency 0 trials
- Alpha-2-plasmin inhibitor deficiency 0 trials
- Combined deficiency of factor V and factor VIII 0 trials Sub-types →
- Combined deficiency of factor VII and factor X 0 trials
- Congenital high-molecular-weight kininogen deficiency 0 trials
- Dysplasminogenemia 0 trials
- Factor V amsterdam bleeding disorder 0 trials
- Factor V atlanta bleeding disorder 0 trials
- Factor V deficiency 0 trials Sub-types →
- Factor V short isoforms-related bleeding disorder 0 trials
- Factor XIII deficiency 0 trials Sub-types →
- Hemorrhagic disease due to alpha-1-antitrypsin Pittsburgh mutation 0 trials
- Inherited prekallikrein deficiency 0 trials
- Multiple sclerosis-ichthyosis-factor VIII deficiency syndrome 0 trials
- Plasminogen deficiency, type II 0 trials
- Thrombomodulin-related bleeding disorder 0 trials
-
Thrombotic microangiopathy 26 trials · 151 incl. sub-types
2 sub-types
- Thrombocytopenic purpura 8 trials · 116 incl. sub-types Sub-types →
- Atypical hemolytic-uremic syndrome 19 trials Sub-types →
-
Thrombophilia 12 trials · 75 incl. sub-types
4 sub-types
- Inherited thrombophilia 0 trials · 28 incl. sub-types Sub-types →
- Thrombotic thrombocytopenic purpura 15 trials · 20 incl. sub-types Sub-types →
- Disseminated intravascular coagulation 15 trials Sub-types →
- Protein S deficiency 3 trials Sub-types →
-
Hemolytic-uremic syndrome 7 trials · 24 incl. sub-types
2 sub-types
- Hereditary hemolytic uremic syndrome 0 trials · 19 incl. sub-types Sub-types →
- Infection-related hemolytic uremic syndrome 0 trials · 2 incl. sub-types Sub-types →
-
Hemorrhagic disease of newborn 1 trial
-
Marantic endocarditis 0 trials
-
Prekallikrein deficiency 0 trials
1 sub-type
- Inherited prekallikrein deficiency 0 trials
Most studied deeper sub-types
-
New hope for rare bleeding disorder: coagadex trial targets AL amyloidosis
Disease control CancelledThis phase 3 study tests Coagadex, a human clotting factor X, in 15 adults with acquired factor X deficiency caused by AL amyloidosis. The goal is to see if it safely stops active bleeding and helps manage bleeding during surgery. Participants receive the drug on demand for bleed…
Phase 3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
One-Time gene therapy could free hemophilia patients from frequent infusions
Disease control OngoingThis study tests a one-time gene therapy (valoctocogene roxaparvovec) in 6 Japanese men with severe hemophilia A. The goal is to help their bodies produce their own clotting factor, reducing or stopping the need for regular factor VIII infusions. Participants will be monitored fo…
Phase 3 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Gene therapy for hemophilia a: how long does it last?
Disease control By invitation onlyThis study checks the long-term safety and effectiveness of a one-time gene therapy (BMN 270) for people with severe hemophilia A. Participants from earlier BioMarin trials will be followed for many years to see if the treatment continues to work and remains safe. The goal is to …
Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Promising ITP drug trial pulled before it even started
Disease control CancelledThis study was designed to test the safety and tolerability of a new drug called HMPL-523 (sovleplenib) in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding problems. The trial was withdrawn before enrolling any pa…
Phase 1 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jun 26, 2026 18:23 UTC
-
Sugar showdown: which sweetener wreaks havoc on your gut?
Knowledge-focused OngoingThis study gives 20 healthy adults drinks containing sucrose (table sugar), glucose, fructose, or plain water, then measures how their bodies respond. Researchers track gut hormones, blood sugar, digestion speed, and other health markers. The goal is to understand the unique effe…
Sponsor: University Hospital, Basel, Switzerland • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Blood test may unlock clotting secrets in burn injuries
Knowledge-focused CancelledThis pilot study is testing whether a specialized blood test called thromboelastography (TEG) can better evaluate clotting problems in people with severe burns. Researchers will track clotting patterns over the first four weeks after injury and see if they relate to burn size or …
Sponsor: Francesco Egro • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
AI takes on blood clotting: can ChatGPT guide surgeons on bleeding?
Knowledge-focused CancelledThis study evaluates whether artificial intelligence models can accurately interpret ROTEM blood clotting tests and recommend treatments for coagulopathy. Researchers will compare AI decisions to those of a panel of clinical experts using data from adults undergoing elective card…
Sponsor: Ondokuz Mayıs University • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC